RxDoctor Payments DataLook up a doctor →

Chelsea Cramer

Adult Health · Somers Point, NJNPI 1881144988

Payments from drug & device makers

$8,418in general payments, 2019–2025

Across 395 payments — averaging $21.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$974
  • Incyte Corporation$602
  • AstraZeneca$601
  • Astellas Pharma US Inc$524
  • Bristol Myers Squibb$405
  • Pfizer$401
  • plus $5K from 53 others

What the payments were for

  • Food & beverage$7,69691%
  • Education$7229%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,418 in reported general payments places this provider in the 95th percentile of 1,135 adult health providers in New Jersey.

See all adult health providers in New Jersey

Medicare billing

Part B allowed, 2024
$113,807
Medicare patients
105
Services billed
4,130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix225$658,568
VitrakviLarotrectinib Sulfate13$467,048
VerzenioAbemaciclib20$415,250
TalzennaTalazoparib Tosylate26$367,607
XtandiEnzalutamide34$308,044
Abiraterone Acetate146$262,720
BrukinsaZanubrutinib20$257,287
ImbruvicaIbrutinib16$240,902
IbrancePalbociclib12$191,763
CalquenceAcalabrutinib Maleate13$184,113
MekinistTrametinib Dimethyl Sulfoxide12$174,190
TafinlarDabrafenib Mesylate12$160,437
EliquisApixaban52$70,991
XareltoRivaroxaban29$44,078
Imatinib Mesylate20$5,752

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx$15$658,568225 claims
PfizerTalzenna, Ibrance, Eliquis$401$630,36090 claims
BayerVitrakvi$238$467,04813 claims
Lilly USA, LLCVerzenio$220$415,25020 claims
NovartisMekinist, Tafinlar$346$334,62724 claims
Astellas Pharma US IncXtandi$524$308,04434 claims
Beigene USA, Inc.Brukinsa$153$257,28720 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$118$240,90216 claims
AstraZenecaCalquence$601$184,11313 claims
Johnson & JohnsonXarelto$128$44,07829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,135 adult health providers in New Jersey.

Other adult health in Somers Point

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →